Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus CEPHAPIRIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus CEPHAPIRIN SODIUM.
CEFUROXIME SODIUM vs CEPHAPIRIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
500 mg to 1 g IM or IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic